辛妥珠单抗

辛妥珠单抗
单克隆抗体
种类	完整抗体
目標	LOXL2（英语：LOXL2）
臨床資料
ATC碼	未分配;
识别信息
CAS号	1318075-13-6
IUPHAR/BPS	8412;
ChemSpider	none;
UNII	11Z5AIU653;
化学信息
化学式	C6558H10134N1736O2037S50
摩尔质量	147,492.33 g·mol−1

辛妥珠单抗（INN：simtuzumab；开发代号：GS-6624）是一种人源化单克隆抗体，设计用于治疗纤维化。^[1]它与LOXL2（英语：LOXL2）结合并充当免疫调节剂。^[2]^[3]2016年1月，吉利德科学公司因缺乏疗效而终止了针对特发性肺纤维化（IPF）患者的II期临床研究。^[4]

参考资料

^ Statement On A Nonproprietary Name Adopted By The USAN Council - Simtuzumab, American Medical Association.
^ Muir, Andrew J.; Levy, Cynthia; Janssen, Harry L. A.; Montano-Loza, Aldo J.; Shiffman, Mitchell L.; Caldwell, Stephen; Luketic, Velimir; Ding, Dora; Jia, Catherine; McColgan, Bryan J.; McHutchison, John G. Simtuzumab for Primary Sclerosing Cholangitis: Phase 2 Study Results With Insights on the Natural History of the Disease. Hepatology (Baltimore, Md.). 2019-02, 69 (2). ISSN 1527-3350. PMID 30153359. doi:10.1002/hep.30237.
^ World Health Organization. International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 107 (PDF). WHO Drug Information. 2012, 26 (2).
^ Gilead Terminates Phase 2 Study of Simtuzumab in Patients With Idiopathic Pulmonary Fibrosis. Gilead. 5 January 2016.

[1] Statement On A Nonproprietary Name Adopted By The USAN Council - Simtuzumab, American Medical Association.

[2] Muir, Andrew J.; Levy, Cynthia; Janssen, Harry L. A.; Montano-Loza, Aldo J.; Shiffman, Mitchell L.; Caldwell, Stephen; Luketic, Velimir; Ding, Dora; Jia, Catherine; McColgan, Bryan J.; McHutchison, John G. Simtuzumab for Primary Sclerosing Cholangitis: Phase 2 Study Results With Insights on the Natural History of the Disease. Hepatology (Baltimore, Md.). 2019-02, 69 (2). ISSN 1527-3350. PMID 30153359. doi:10.1002/hep.30237.

[3] World Health Organization. International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 107 (PDF). WHO Drug Information. 2012, 26 (2).

[4] Gilead Terminates Phase 2 Study of Simtuzumab in Patients With Idiopathic Pulmonary Fibrosis. Gilead. 5 January 2016.

[1]

[2]

[3]

[4]